HIV Infection
Conditions
Keywords
HIV, antiretroviral therapy
Brief summary
The study aims to assess the safety and efficacy of darunavir 800mg plus the co-formulated elvitegravir/cobicistat/tenofovir disoproxil fumarate (DF)/emtricitabine (Stribild) tablet as a simplification strategy for the treatment of HIV infection in HIV-infected subjects who have had previous antiretroviral treatment experience with multiple-drug regimens. We hypothesize that elvitegravir/cobicistat/tenofovir DF/emtricitabine with darunavir will offer a safe and efficacious treatment simplification strategy for HIV positive patients currently receiving multiple-drug regimens to control their HIV infection.
Detailed description
Eligible, consenting subjects will be assessed at baseline and weeks 2, 12, 24, 36, and 48. Study medications will be dispensed at all visits except week 2, and all participants will commence taking open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/emtricitabine/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food, following study procedures at baseline. Assessments at the study visits will include: 1. Complete physical exam including height and weight at baseline; symptom-directed physical exam and weight at other visits 2. Adverse clinical events including serious adverse events (hospitalizations etc.) and medication changes at every visit. 3. HIV RNA every 4 weeks. 4. CD4 and CD8 absolute counts and % at all visits except week 2. 5. Platelet count, aspartate amino transferase (AST), creatinine, estimated glomerular filtration rate (eGFR), phosphorus, urinalysis, and urine albumin to creatinine ratio (UACR) at each visit. 6. Fasting lipids (total, HDL, and LDL cholesterol and triglycerides), apolipoprotein B, high-sensitivity C- reactive protein (hsCRP) at baseline, week 24, and week 48. 7. Pregnancy test for women of child-bearing potential (as defined above) at every visit except week 2. In addition, pregnancy tests will be performed monthly for women of child-bearing potential; between study visits these may be done at home. 8. A plasma sample (3 mL) will be collected and stored once at baseline for all subjects, and used for measurement of darunavir trough (pre-dose) concentration in subjects receiving darunavir in their pre-study regimen. 9. All subjects will take their study medication under observation in the clinic on Day 14, and plasma samples (3mL) for pharmacokinetic testing will be drawn immediately pre-dose and at 1, 2, 3, 4, 5, 6, and 8 hours post-dose. Subjects will return the following day before taking their Day 15 dose for a 24-hour post-dose sample. 10. Peripheral blood mononuclear cells (PBMCs) will be collected and stored at baseline for possible future study-related testing. 11. The following questionnaires will be completed by participants prior to other study procedures at baseline and at weeks 24 and 48: MOS-HIV quality of life questionnaire; HIVTSQ; ACTG treatment adherence questionnaire; and the medication adherence self-report inventory (MASRI).
Interventions
DRUGTreatment simplification
Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
Sponsors
Gilead Sciences
University of British Columbia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV positive adults \> or = 19 years of age * receiving stable therapy including one or two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), in conjunction with a once-daily protease inhibitor (PI) (atazanavir, lopinavir or darunavir) and twice daily raltegravir or once daily dolutegravir * Virologic suppression for \>6 months, defined as plasma viral load (VL) consistently \< 200 copies/mL with no evidence of prior virologic rebound (VL \> 1000 copies/mL) on the NRTI/PI/Raltegravir regimen, AND VL \< 50 copies/mL at time of study screening * Estimated glomerular filtration rate (eGFR) \> o r= 70mL/min at screening
Exclusion criteria
* Prior documented viral rebound \> 1000 copies/mL on any raltegravir-containing regimen * Evidence of resistance mutations compromising raltegravir or elvitegravir activity on prior genotypes. * Evidence of clinically significant resistance to tenofovir on any previous genotype tests: K65R mutation, or 3 or more thymidine-analogue associated mutations (TAMS) compromising tenofovir activity * Evidence of resistance mutations significantly compromising darunavir activity on any previous genotypic tests * Current use of any nonnucleoside reverse transcriptase inhibitor (NNRTI) * Pregnancy or breast-feeding * Contraindications to tenofovir/FTC, elvitegravir, or cobicistat (e.g. previous significant toxicity, intolerance or drug interactions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma HIV RNA | 12 weeks | Proportion of individuals with plasma HIV RNA \<200copies/mL at 12 weeks following regimen switch |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CD4 cell count, CD4% and CD4/CD8 ratio | 12, 24 and 48 weeks | Change in CD4 cell count, CD4% and CD4/CD8 ratio from study baseline to 12, 24 and 48 weeks after switch. |
| serum creatinine and estimated glomerular filtration rate (eGFR) | 12, 24, and 48 weeks | Change in serum creatinine and eGFR from baseline to 12, 24 weeks and 48 weeks. |
| Adverse event discontinuations | 48 weeks | Proportion of adverse events experienced necessitating switch to original regimen |
| fasting lipid parameters (total cholesterol, LDL, HDL, triglycerides, and apolipoprotein B [apoB]), AST to platelet ratio index (APRI) score, and high-sensitivity C-reactive protein (hsCRP) | 24 and 48 weeks | Changes in fasting lipid parameters (total cholesterol, LDL, HDL, triglycerides, and apolipoprotein B \[apoB\]), AST to platelet ratio index (APRI) score, and high-sensitivity C-reactive protein (hsCRP) between baseline and 24 and 48 weeks. |
| plasma HIV RNA | weeks 12, 24 and 48 | Proportion of individuals with plasma HIV RNA \< 50 copies/mL at weeks 12, 24 and 48 post switch |
| HIV Treatment Satisfaction Questionnaire (HIVTSQ) scores and quality of life indicators (MOS-HIV scores) | weeks 24 and 48 | Changes in HIV Treatment Satisfaction Questionnaire (HIVTSQ) scores and quality of life indicators (MOS-HIV scores) between baseline and weeks 24 and 48 following switch. |
| Adherence | 24 and 48 weeks | Changes in antiretroviral adherence from baseline to 24 and 48 weeks. Adherence will be assessed using two measures: the ACTG treatment adherence questionnaire and the Medication adherence self-report inventory (MASRI). |
| Elvitegravir plasma concentrations | Day 14 | Elvitegravir concentrations will be measured at day 14 |
| Adverse events | 48 weeks | Adverse events necessitating a resumption of the previous antiretroviral regimen, and all serious adverse events will be recorded. |
| Darunavir plasma concentration | week 2 | Change in darunavir trough concentration from baseline to week 2 for individuals receiving darunavir at baseline |
Countries
Canada
Outcome results
None listed